Latest news with #AERB
Time of India
3 days ago
- Health
- Time of India
Late Bhanutai Gadkari Memorial Diagnostic Centre inaugurated: MRI at Rs1,200, CT Scan at Rs800, X-ray at Rs100
Nagpur: A state-of-the-art 6,000 sq ft facility in north Nagpur will be offering essential diagnostic and dialysis services at some of the lowest rates in the country — MRI for Rs1,200, CT Scan for Rs800, and digital X-ray for just Rs100, and major blood tests at Rs300, which otherwise cost thousands. Remarkably, it is India's first diagnostic centre equipped entirely with "Made-in-India" machines. The late Bhanutai Gadkari Memorial Diagnostic Centre, which was inaugurated on Sunday, has come as a major boost for healthcare infrastructure in north Nagpur. Located at Kamal Chowk, Lashkaribagh, the centre is dedicated to memory of Bhanutai Gadkari, mother of Union minister for road transport and highways, Nitin Gadkari, who presided over the programme when chief minister Devendra Fadnavis inaugurated the facility. "This diagnostic centre will be a milestone in the healthcare sector. Combining empathy with service, it sets an example of how indigenous technology can be used to bring down the cost of essential diagnostics for the common man," said Fadnavis while praising Gadkari's initiative. Gadkari, on an emotional note, said that the centre is not a commercial project, but a service mission inspired by his mother's legacy for compassion and empathy. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Your IQ Is 140 If You Can Answer 10 of These Questions Correctly. IQ International Undo by Taboola by Taboola "From my first day in public life, her blessings guided me to serve the poor and suffering," said Gadkari and made an appeal to include bone marrow, sickle cell and thalassaemia treatments under the Mahatma Jyotiba Phule Jan Arogya Yojana. The fully air-conditioned centre, run by the late Bhanutai Gadkari Gramin Vikas Sanstha, features a modern waiting area, paperless operations, high-capacity servers, and trained technical staff. All MRI and CT scan machines have been manufactured in India, in collaboration with AMTZ (Andhra Pradesh MedTech Zone), significantly cutting costs compared to imported equipment. "This is the first time in India that a diagnostic centre has been established with 100% indigenous machines. We used to import MRI machines for Rs6 crore. Now, we are making them at Rs2 crore and exporting them too," said Dr Jitendra Sharma, managing director of AMTZ. # WHAT CENTRE OFFERS MRI – Rs1,200: High-end 1.5 Tesla imaging with 16-channel MUSIC technology ensuring quick scans with excellent image quality CT Scan — Rs800: BIS, AERB and CDSCO-approved fast scanning machines. Full chest scans done in just 6 seconds Digital X-ray — Rs100; high-resolution, modern digital imaging Dialysis — Rs750 standard, only Rs250 if NMC provides ₹500 subsidy—free dialysis for donor-backed patients Pathology Tests — Rs300; over 40 common tests included Pharmacy — Generic medicines available at 10% discount
The Hindu
06-07-2025
- Business
- The Hindu
Atomic energy board grants operational licence to two home-built 700 MWe reactors in Gujarat
India's nuclear regulator, the Atomic Energy Regulatory Board (AERB), has granted operation licence for two indigenously developed 700 MWe Pressurised Heavy Water Reactors at the Kakrapar Atomic Power Station (KAPS) in Gujarat. The KAPS-3 reactor was commissioned at full power in August 2023, while the KAPS-4 unit followed the same month a year later. "The AERB has concluded the design and commissioning safety reviews and issued the Licence for Operation of Units 3 and 4 of KAPS, the country's first 700 MWe indigenous Pressurized Heavy Water Reactors [PHWRs]," a statement from the regulator said. Since the 700 MWe reactor was the first of its kind, the licensing process involved rigorous multi-tiered safety reviews and assessment of the reactor design, covering the entire life cycle in multiple stages from siting, construction to commissioning at full-power. The Nuclear Power Corporation of India Limited (NPCIL) received the Licence for Operation for KAPS 3&4 from the AERB for a period of five years on July 3. The issuance of the licence is a shot in the arm for the NPCIL, which is spearheading building 10 PHWRs of 700 MWe each in fleet mode. India has 15 PHWRs of 220 MWe and two of 540 MWe capacity operational at various sites across the country. The 540 MWe PHWR design was upgraded to 700 MWe and the first pair of such reactors are operational at Kakrapar. A similar 700 MWe reactor at Rawatbhata in Rajasthan began commercial operations in March this year. Besides the AERB, several reactor safety experts from the technical support organisations made significant contributions towards review of the design and commissioning results, which spanned almost 15 years. As a part of Phase-C commissioning, KAPS-3 received permission for full power operation in August 2023, followed by KAPS-4 in August 2024. After further review of plant performance close to rated power, the AERB has now granted the License for Operation to the NPCIL for five years.
Hindustan Times
06-07-2025
- Business
- Hindustan Times
AERB grants operational license to two home-built 700 MW PHWRS in Gujarat
New Delhi, India's nuclear regulator AERB has granted operation license for two indigenously developed 700 MW Pressurised Heavy Water Reactors at the Kakrapar Atomic Power Station in Gujarat. AERB grants operational license to two home-built 700 MW PHWRS in Gujarat The KS-3 reactor was commissioned at full power in August 2023, while the KS-4 unit followed the same month a year later. "The Atomic Energy Regulatory Board has concluded the Design and Commissioning Safety Reviews and issued the License for Operation of Units 3 and 4 of KS-3&4, the country's first 700 MWe indigenous Pressurized Heavy Water Reactors ," a statement from the regulator said. Since the 700 MW reactor was the first of its kind, the licensing process involved rigorous multi-tiered safety reviews and assessment of the reactor design, covering the entire life cycle in multiple stages from siting, construction to commissioning at full-power. The Nuclear Power Corporation of India Limited received the License for Operation for KS 3&4 from the AERB for a period of five years on July 3. The issuance of the license is a shot in the arm for NPCIL, which is spearheading building 10 PHWRs of 700 MWe each in fleet mode. India has 15 PHWRs of 220 MWe and two of 540 MWe capacity operational at various sites across the country. The 540 MWe PHWR design was upgraded to 700 MWe and the first pair of such reactors are operational at Kakrapar. A similar 700 MW reactor at Rawatbhata in Rajasthan began commercial operations in March this year. Besides AERB, several reactor safety experts from the Technical Support Organisations made significant contributions towards review of the Design and Commissioning results, which spanned almost 15 years. As a part of Phase-C Commissioning, KS-3 received permission for full power operation in August 2023, followed by KS-4 in August 2024. After further review of plant performance close to rated power, AERB has now granted the License for Operation to NPCIL for a period of five years. This article was generated from an automated news agency feed without modifications to text.
&w=3840&q=100)
Business Standard
06-07-2025
- Business
- Business Standard
AERB grants operational license to two home-built 700 MW PHWRS in Gujarat
India's nuclear regulator AERB has granted operation license for two indigenously developed 700 MW Pressurised Heavy Water Reactors at the Kakrapar Atomic Power Station (KAPS) in Gujarat. The KAPS-3 reactor was commissioned at full power in August 2023, while the KAPS-4 unit followed the same month a year later. "The Atomic Energy Regulatory Board (AERB) has concluded the Design and Commissioning Safety Reviews and issued the License for Operation of Units 3 and 4 of KAPS-3&4, the country's first 700 MWe indigenous Pressurized Heavy Water Reactors (PHWRs)," a statement from the regulator said. Since the 700 MW reactor was the first of its kind, the licensing process involved rigorous multi-tiered safety reviews and assessment of the reactor design, covering the entire life cycle in multiple stages from siting, construction to commissioning at full-power. The Nuclear Power Corporation of India Limited (NPCIL) received the License for Operation for KAPS 3&4 from the AERB for a period of five years on July 3. The issuance of the license is a shot in the arm for NPCIL, which is spearheading building 10 PHWRs of 700 MWe each in fleet mode. India has 15 PHWRs of 220 MWe and two of 540 MWe capacity operational at various sites across the country. The 540 MWe PHWR design was upgraded to 700 MWe and the first pair of such reactors are operational at Kakrapar. A similar 700 MW reactor at Rawatbhata in Rajasthan began commercial operations in March this year. Besides AERB, several reactor safety experts from the Technical Support Organisations made significant contributions towards review of the Design and Commissioning results, which spanned almost 15 years. As a part of Phase-C Commissioning, KAPS-3 received permission for full power operation in August 2023, followed by KAPS-4 in August 2024. After further review of plant performance close to rated power, AERB has now granted the License for Operation to NPCIL for a period of five years.
Hindustan Times
28-06-2025
- Health
- Hindustan Times
Teen beats cancer after ‘ultra-high' dose nuclear therapy at Mumbai's TMC
In a pathbreaking medical feat, a 17-year-old boy suffering from relapsed Neuroblastoma, an aggressive form of paediatric cancer, was given a new lease of life through an experimental nuclear therapy conducted at ACTREC (Advanced Centre for Treatment, Research and Education in Cancer), R&D wing of the Tata Memorial Centre in Navi Mumbai. The boy, who was first diagnosed in 2022 at age 14, had undergone a stem cell transplant but suffered a relapse earlier this year, leaving doctors with limited options.(Unsplash/Representational) Doctors at the facility administered an ultra-high dose of radioactive 131-Iodine MIBG therapy, 800 millicurie, nearly three times the permissible limit set by the Atomic Energy Regulatory Board (AERB), making it the highest dosage ever used in India for treating Neuroblastoma. The procedure, conducted on May 5, was the result of a meticulously planned, three-month-long collaborative effort by six departments at ACTREC, with guidance from Memorial Sloan Kettering Cancer Center in the US. 'This form of cancer is almost never diagnosed early. Most cases, by the time they come to us, are already in stage four,' said Dr Venkatesh Rangarajan, head of nuclear medicine at Tata Memorial Hospital. The boy, who was first diagnosed in 2022 at age 14, had undergone a stem cell transplant but suffered a relapse earlier this year, leaving doctors with limited options. That's when the medical team proposed 131-I MIBG—a form of targeted nuclear medicine therapy. While Indian protocols have previously capped radioactive dosage at 300 millicurie, this particular case warranted a drastic step forward. 'Administering 800 millicurie required exceptional safety measures and a special nod from the AERB,' said Dr Rangarajan. 'The major challenge was to shield healthcare staff and others from gamma radiation, which meant constructing an isolated high-safety ward and ensuring no one except the core team was exposed.' Also read: He stole to fund his son's cancer treatment, was still behind bars when boy died One of the most dangerous side effects of such high-dose radioisotope therapy is bone marrow suppression. To mitigate this, doctors harvested and stored the patient's bone marrow before treatment. It was reinfused into his body after the therapy concluded. Another unusual condition for the therapy: the patient had to remain in complete isolation for five days. Today, the boy is back home, cancer-free, and dreaming of becoming a doctor himself. 'His resilience and the team's extraordinary commitment made this success possible,' said Dr Gupta.
